

| <b>EPF wishes to thank the European Commission for its support in 2019 in relation to EPF's role in the following projects</b> |                                |                   |
|--|--------------------------------|-------------------|
|  | EC Contribution used in 2019   | % of total income |
| <b>TOTAL European Commission support to projects 2019</b>  | <b>€ 188,009.61</b>            |                   |
| CHRODIS +  | € 25,190.75                    | 0.9%              |
| ComparEU   | € 31,468.16                    | 1.1%              |
| DigitalHealthEurope  | € 24,273.65                    | 0.9%              |
| EFO EUPATI   | € 82,853.30                    | 3.0%              |
| EHDEN  | € 13,402.80                    | 0.5%              |
| EU-PEARL   | € 1,316.32                     | 0.0%              |
| IMMUCAN  | € 5,914.48                     | 0.2%              |
| PREFER   | € 3,590.15                     | 0.1%              |
| <b>EPF wishes to thank the following donors for their support:</b>   |                                |                   |
|  | Contribution to the Operations | % of total income |
| <b>Operational &amp; Engagement - work plan 2019/ Project Development 2019</b>   | <b>€ 855,150.00</b>            |                   |
| European Commission  | € -                            | 0.0%              |
| AbbVie   | € 35,000.00                    | 1.3%              |
| Amgen  | € 35,000.00                    | 1.3%              |
| Celgene  | € 30,000.00                    | 1.1%              |
| CSL Behring  | € 10,000.00                    | 0.4%              |
| Edwards Lifescience SA   | € 25,000.00                    | 0.9%              |
| Eli Lilly  | € 15,000.00                    | 0.5%              |
| Gilead Sciences Europe   | € 40,000.00                    | 1.4%              |
| Grunenthal   | € 5,000.00                     | 0.2%              |
| GSK  | € 30,000.00                    | 1.1%              |
| Janssen  | € 50,000.00                    | 1.8%              |
| Medicines for Europe   | € 20,000.00                    | 0.7%              |
| MSD  | € 80,000.00                    | 2.9%              |
| Novartis Pharma AG   | € 100,000.00                   | 3.6%              |
| Pfizer Inc   | € 25,000.00                    | 0.9%              |
| Philips  | € 10,000.00                    | 0.4%              |
| F. Hoffman-La Roche  | € 50,000.00                    | 1.8%              |
| Sanofi Aventis   | € 50,000.00                    | 1.8%              |
| Servier  | € 10,000.00                    | 0.4%              |
| Takeda   | € 40,000.00                    | 1.4%              |
| Teva   | € 110,000.00                   | 4.0%              |
| UCB  | € 25,000.00                    | 0.9%              |
| Vertex   | € 40,000.00                    | 1.4%              |
| Membership   | € 20,150.00                    | 0.7%              |
| <b>Capacity Building Programme 2019</b>  | <b>€ 480,655.26</b>            |                   |
|  | Contribution to the CBP        | % of total income |
| Alexion  | € 14,000.00                    | 0.5%              |
| Amgen  | € 5,000.00                     | 0.2%              |
| Baxter   | € 10,000.00                    | 0.4%              |
| Biogen   | € 20,000.00                    | 0.7%              |
| EFPIA (DSL)  | € 136,655.26                   | 4.9%              |
| EFPIA/ Vaccines Europe   | € 65,000.00                    | 2.3%              |
| EIT Health (DSL)   | € 20,000.00                    | 0.7%              |
| ENHA   | € 10,000.00                    | 0.4%              |
| GSK  | € 30,000.00                    | 1.1%              |
| Kyowa Kirin  | € 10,000.00                    | 0.4%              |
| LEO Pharma   | € 15,000.00                    | 0.5%              |
| Medtech (DSL)  | € 10,000.00                    | 0.4%              |
| Merck  | € 35,000.00                    | 1.3%              |
| MNI (Medical Nutrition International)  | € 20,000.00                    | 0.7%              |
| Novo-nordisk   | € 30,000.00                    | 1.1%              |
| Pfizer Inc   | € 25,000.00                    | 0.9%              |
| Teva   | € 25,000.00                    | 0.9%              |
| <b>Patients Active in Research and Dialogue for an Improved Generation of Medicine "PARADIGM"</b>                              | <b>€ 427,508.74</b>            |                   |

|  |                       | % of total income |
|--|-----------------------|-------------------|
| Innovative Medicines Initiative (IMI JU) PARADIGM Funding  | € 282,112.93          | 10.2%             |
| Industry cash contribution (Amgen, Lundbeck, MSD, Pfizer, VFA)   | € 145,395.81          | 5.2%              |
| <b>Patient Academy on Therapeutic Innovation "EUPATI Programme" 2017-2019</b>  | <b>€ 238,022.04</b>   |                   |
|  |                       | % of total income |
| Industry consortium 2017-2019 (AbbVie, Amgen, AstraZeneca UK, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, DIA, F. Hoffmann-La Roche, GSK, Janssen, LEO Pharma, Merck, MSD, Novartis, Novo Nordisk, Pfizer, Shire, UCB, Takeda, VFA) | € 238,022.04          | 8.6%              |
| <b>CONGRESS 2019</b>   | <b>€ 541,110.00</b>   |                   |
| AbbVie   | € 20,000.00           | 0.7%              |
| Alexion  | € 13,500.00           | 0.5%              |
| Baxter   | € 10,000.00           | 0.4%              |
| Bayer  | € 10,000.00           | 0.4%              |
| BMS  | € 25,000.00           | 0.9%              |
| Boehringer   | € 20,000.00           | 0.7%              |
| Celgene  | € 25,000.00           | 0.9%              |
| EFPIA  | € 50,000.00           | 1.8%              |
| EIT Health   | € 20,000.00           | 0.7%              |
| Fresenius Kabi   | € 10,000.00           | 0.4%              |
| Janssen  | € 40,000.00           | 1.4%              |
| Kyowa Kirin  | € 10,000.00           | 0.4%              |
| LEO Pharma   | € 10,000.00           | 0.4%              |
| Merck  | € 40,000.00           | 1.4%              |
| MYLAN  | € 10,000.00           | 0.4%              |
| Novartis Pharma AG   | € 40,000.00           | 1.4%              |
| Novo Nordisk   | € 25,000.00           | 0.9%              |
| F. Hoffman-La Roche  | € 10,000.00           | 0.4%              |
| Servier  | € 15,000.00           | 0.5%              |
| Takeda   | € 15,000.00           | 0.5%              |
| UCB  | € 10,000.00           | 0.4%              |
| Participation Fees   | € 106,990.00          | 3.9%              |
| Membership   | € 5,620.00            | 0.2%              |
| <b>Other income</b>  | <b>€ 41,857.77</b>    | <b>1.5%</b>       |
| <b>TOTAL INCOME 2019</b>   | <b>€ 2,772,313.42</b> |                   |